Literature DB >> 2188194

Immunohistochemical evidence for IgE involvement in Graves' orbitopathy.

R B Raikow1, M H Dalbow, J S Kennerdell, K Compher, L Machen, W Hiller, D Blendermann.   

Abstract

Orbital muscle and adipose tissues from seven Graves' orbitopathy patients were studied with in situ assays for IgE. The cases varied in disease severity and site biopsied. Two monoclonal and one polyclonal anti-IgE reagents produced similar results. Identically prepared monoclonal anti-IgM and anti-IgG antibodies and tissues obtained from five patients treated for unrelated orbital disorders were used as controls. Graves' tissues exhibited extravasated leukocytes and leukocyte-rich vessels. These leukocytes were mostly lymphoid. Some basophils and mast cells were identified and polymorphonuclear cells were abundant within vessels of adipose tissue. IgE-positive material was found in association with the majority of leukocytes and with muscle fibers. Parallel sections reacted with anti-IgM antibody were negative, whereas anti-IgG produced diffuse staining with no specific structures highlighted. Control, non-Graves' tissues had no evidence of immune cell activity and were either negative or displayed reactions with anti-IgE reagents that were in most cases different from those of Graves' tissue. Serum IgE was measured in six of the seven patients and was elevated in the two patients with fulminating disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188194     DOI: 10.1016/s0161-6420(90)32548-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Surface expression and release of soluble forms of CD8 and CD23 in CD40- and IL-4-activated mononuclear cells from patients with Graves' disease (GD).

Authors:  M Itoh; K Uchimura; N Hayakawa; M Makino; R Hayashi; M Nagata; H Kakizawa; A Nagasaka; H Sakamoto; H Kuzuya
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

2.  The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.

Authors:  K Van der Weerd; P M Van Hagen; B Schrijver; D J Kwekkeboom; W W De Herder; M R J Ten Broek; P T E Postema; J J M Van Dongen; F J T Staal; W A Dik
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

3.  THYROTROPIN-RECEPTOR ANTIBODIES, IMMUNOGLOBULIN E AND ANTINUCLEAR ANTIBODIES IN PATIENTS WITH GRAVES' DISEASE AND GRAVES' ORBITOPATHY.

Authors:  M Stoynova; A Shinkov; G Kirilov; R Kovatcheva
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

4.  Immunohistology of eye muscle in idiopathic orbital inflammatory disease (pseudotumor), Graves' ophthalmopathy and healthy controls.

Authors:  T Lenderink; M J Jager; J A Bruijn; R J de Keizer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

Review 5.  Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?

Authors:  T Mizokami; M Salvi; J R Wall
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 6.  Immunoglobulin E-Mediated Autoimmunity.

Authors:  Marcus Maurer; Sabine Altrichter; Oliver Schmetzer; Jörg Scheffel; Martin K Church; Martin Metz
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

7.  Influence of 4-week or 12-week glucocorticoid treatment on metabolic changes in patients with active moderate-to-severe thyroid-associated ophthalmopathy.

Authors:  Xiaoman Chen; Buatikamu Abudukerimu; Qin Li; Qing Li; Jie Qiao; Dongping Lin; Chunhua Sui; Lin Ye; Hualing Zhai; Boren Jiang; Ningjian Wang; Mengda Jiang; Xiaofeng Tao; Ziyang Shao; Chenfang Zhu; Yubo Ma; Ping Xiong; Jing Sun; Huifang Zhou; Bing Han; Yingli Lu
Journal:  Clin Transl Sci       Date:  2021-05-03       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.